Aurinia Publishes the Results of Lupkynis (voclosporin) in P-III AURORA 1 Study for Patients with Active Lupus Nephritis in The Lancet
Shots: The P-III AURORA 1 study involves assessing the efficacy and safety of Lupkynis (23.7mg, bid) + MMF and low-dose corticosteroids vs MMF and low-dose corticosteroids alone in 357 adults with SLE and LN The trial met its 1EP and 2EPs i.e. complete renal response rates (41% vs 23%) @52wks. and 50% reduction from baseline […]